This trial is terminated!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Breast Cancer
and you are
between 18 and 70
years old
3
This is a trial in the final phase before the treatment is released on the market.
Show me locations

The purpose

The purpose of this study is to compare the pathological complete response (pCR) rate in triple-negative or Her2 positive breast cancer patients treated with neoadjuvant docetaxel, anthracycline and cyclophosphamide (TAC) or docetaxel and cyclophosphamide (TC) regimen.

Provided treatments

  • Drug: Docetaxel, Anthracycline (Doxorubicin or Epirubicin), Cyclophosphamide
  • Drug: Docetaxel, cyclophosphamide
Tris trial is registered with FDA with number: NCT00912444. The sponsor of the trial is Shanghai Jiao Tong University School of Medicine and it is looking for 102 volunteers for the current phase.
Official trial title:
A Multi-Center, Randomized Study of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Neoadjuvant Treatment of Triple-Negative or Her2 Positive Breast Cancer